Similar to Aurora and MedMen, Tilray looks to be facing a serious cash crunch in the not-so-distant future. Having ended the previous year with $517.6 million in cash, cash equivalents, and short-term investments, ongoing losses and acquisitions have pushed its total cash balance below $97 million. Tilray did sign a $60 million two-year credit facility late last month, but that looks to be insufficient given how quickly the company is burning through its cash.